医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Central Nervous System Market Examined in Insightful Global Industry Analysts Report Available at MarketPublishers.com

2013年05月01日 AM01:40
このエントリーをはてなブックマークに追加


 

LONDON

The global market for central nervous system (CNS) therapeutics is forecast to be worth USD 133bn by end-2018. The growth will be chiefly fuelled by an increase in disease prevalence rates owing to the globe’s ageing population, launch of a novel class of drugs, and increased healthcare spending. The United States is the largest regional CNS market, whereas the Asia-Pacific market’s revenues are growing at the fastest rate (about 6% CAGR over the forecast period). Anti-epilepsy drugs are the most rapidly evolving product market.

However, the CNS therapeutics market presently keeps on experiencing certain challenges due to the continual patent expiration of brand-name drugs from various big companies, like Johnson & Johnson, UCB, Pfizer, and GlaxoSmithKline, among others. In the next decade, the market is expected to face enormous pressure due to severe generic erosion as multimillion-dollar drugs by annual sales fall under momentary price pressures. Moreover, branded drug makers will be troubled by healthcare cost rationing and government caps.

Insightful report “CNS Therapeutics: Market Research Report” elaborated by Global Industry Analysts provides an in-depth analysis of the global CNS therapeutics market by the major product groups, such as anti-Alzheimer’s, anti-Parkinson’s, anti-epilepsy, pain management (includes migraine, nociceptive and neuropathic pain), anti-psychotics, anti-depressants, and others (includes multiple sclerosis, insomnia and ADHD). Separate annual market estimates (historical and current) and forecasts up to 2018 for the key geographical markets, such as the United States, Canada, Europe, the Asia-Pacific, Latin America, and RoW, are included. The study provides an all-round overview of the key trends and burning issues impacting the market, major growth drivers and restrains, the competitive landscape, M&As, and other strategic industry affairs. Furthermore, the research is supplemented with elaborate profiles of 127 leading and niche market participants.

Report Details:

Title: CNS Therapeutics: Market Research Report

Published: February, 2013

Pages: 1058

Price: US$ 4,950.00

http://marketpublishers.com/report/healthcare/therapy/cns-therapeutics_gia.html

Report Contents:

I.INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations

Disclaimers

Data Interpretation & Reporting Level

Quantitative Techniques & Analytics

Product Definitions and Scope of Study

CNS Disorders

Anti-Alzheimer’s Drugs

Anti-Parkinson’s Drugs

Anti-Epilepsy Drugs

Pain Management Drugs

Anti-Psychotics Drugs

More insightful reports by Global Industry Analysts can be found at http://marketpublishers.com/members/gia/info.html

CONTACT

The Market Publishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax:
+44 207 900 3970
ps@marketpublishers.com
MarketPublishers.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • BioVectra与Keryx Biopharmaceuticals签署枸橼酸铁扩产协议
  • Eternity Healthcare Inc. Enters into Share Exchange Agreement with Guizho Tongren Healthy China Biotechnology Co. Ltd.
  • Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease
  • Chi-Med Initiates Fruquintinib U.S. Clinical Trials
  • Orthocell Granted European Tendon Regeneration Patent